A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy.PURPOSE
 To measure transarterial chemoembolization utilization and survival benefit among patients with hepatocellular carcinoma (HCC) in the Surveillance, Epidemiology, and End Results (SEER) patient population.


 More than 75% of SEER/Medicare patients diagnosed with HCC received no identifiable oncologic treatment. 
SEER
To measure transarterial chemoembolization utilization and survival benefit among patients with hepatocellular carcinoma (HCC) in the Surveillance, Epidemiology, and End Results (SEER) patient population.



Surveillance, Epidemiology, and End Results
Survival was estimated by Kaplan-Meier method and compared by log-rank test. 
Kaplan-Meier method
Survival was estimated by Kaplan-Meier method and compared by log-rank test. 
log-rank test
Propensity-score matching was used to address an imbalance of covariates.



propensity-score matching